+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Aradigm Corporation - logo

Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease. The company’s lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq (ARD-3150) and Lipoquin (ARD-3100) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis and cystic fibrosis. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.

From
From
Global Smoking Cessation Drugs Market 2016-2020 - Product Thumbnail Image

Global Smoking Cessation Drugs Market 2016-2020

  • Report
  • April 2016
  • 74 Pages
From
From
From
From
COPD: Market Intelligence Review and Insights - Product Thumbnail Image

COPD: Market Intelligence Review and Insights

  • Report
  • April 2018
  • 50 Pages
From
US Respiratory Drug Market 2019-2025 - Product Thumbnail Image

US Respiratory Drug Market 2019-2025

  • Report
  • February 2020
From
UK Respiratory Drug Market 2019-2025 - Product Thumbnail Image

UK Respiratory Drug Market 2019-2025

  • Report
  • February 2020
From
From
From
France Respiratory Drug Market 2019-2025 - Product Thumbnail Image

France Respiratory Drug Market 2019-2025

  • Report
  • February 2020
From
From
From
From
From
Loading Indicator
adroll